Mult Scler J Exp Transl Clin
Background: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia.
Objective: We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4+/CD8+ T cells in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in routine practice.
Methods: Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change from baseline in absolute lymphocyte count and CD4+/CD8+ counts at 6-month intervals following dimethyl fumarate initiation.
Results: Charts of 483 patients were abstracted and 476 patients included in the analysis. Mean baseline absolute lymphocyte count (2.23 × 10
Conclusion: Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months correlated with decline in CD4+ and CD8+ T cells and was independent of prior natalizumab. Absolute lymphocyte count monitoring continues to be an effective strategy to identify patients at risk of prolonged lymphopenia.
Neurosciences (Brain & Spine)
Buckle, Guy; Bandari, Daniel; Greenstein, Jeffrey; Gudesblatt, Mark; Khatri, Bhupendra; Kita, Mariko; Repovic, P; Riser, Emily; Weinstock-Guttman, Bianca; Thrower, Ben; Loring, Sherrill; Riester, Katherine; Everage, Nick; Prada, Claudia; Koulinska, Irene; and Mann, Monica, "Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis." (2020). Articles, Abstracts, and Reports. 3172.